35Pharma Inc.
- Address
- 750 Saint-Laurent Boulevard Suite 101
Sponsor Overview
Specializations
Dermatological Therapeutics
35Pharma Inc. concentrates its research efforts on developing treatments for dermatological conditions, with particular emphasis on chronic inflammatory skin disorders. The company's clinical investigation portfolio addresses conditions that significantly impact patient quality of life through visible skin manifestations and associated symptoms.
- Chronic Plaque Psoriasis
- Inflammatory Skin Disease Management
- Topical Therapeutic Formulations
The sponsor's therapeutic development strategy focuses on anti-inflammatory mechanisms and immunomodulatory approaches to address the underlying pathophysiology of chronic skin conditions. Research initiatives explore novel delivery systems and formulation technologies designed to enhance dermal penetration and therapeutic efficacy while minimizing systemic exposure.
Immunological and Autoimmune Disorders
The company maintains an active research programme investigating treatments for immune-mediated inflammatory diseases. This therapeutic area encompasses conditions characterized by dysregulated immune responses and chronic inflammation affecting multiple organ systems.
- Psoriatic Disease Spectrum
- Immune System Modulation
- Chronic Inflammatory Response Control
Clinical investigations focus on interventions that target specific pathways involved in T-cell activation and cytokine-mediated inflammation. The research portfolio addresses the need for treatments that can provide sustained disease control while maintaining acceptable safety profiles for long-term management of chronic autoimmune conditions.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase Ib Dose-Ranging Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Versus Placebo in Combination with Background Therapy in Pulmonary Arterial Hypertension |  Czechia Germany Hungary Poland Spain | Not Yet Recruiting |
| Safety and Efficacy Evaluation of HS135 in Adults With Pulmonary Arterial Hypertension: An Early Phase Clinical Trial | Germany Hungary Poland | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 17 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases2 trials359 other sponsors
Partnered Research Centres
17 centres- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Calle Villarroel 170, 08036 Barcelona
- Address
- Terreno Autovia Mediterraneo A-7 S/n, 29603 Marbella
- Address
- Avenida De Cordoba Sn, 28041 Madrid
- Address
- Paseo De San Vicente 58-182, 37007 Salamanca
- Address
- Avenida Valdecilla Sn, 39008 Santander
Want to get in touch with this sponsor?
Send a question and we'll pass it on to 35Pharma Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.